Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

PHASE3CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

June 5, 2023

Study Completion Date

June 5, 2023

Conditions
Brain Metastases
Interventions
DRUG

18F fluciclovine

18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus

Trial Locations (19)

10016

NYU Langone Health, New York

19104

University of Pennsylvania Health System, Philadelphia

21287

Johns Hopkins Hospital, Baltimore

26506

West Virgina University Cancer Institute, Morgantown

30912

Medical College of Georgia, Augusta University, Augusta

33176

Miami Cancer Institute at Baptist Health, Inc., Miami

35233

University of Alabama at Birmingham, Birmingham

44106

University Hospital Cleveland, Cleveland

44195

Cleveland Clinic, Cleveland

48109

University of Michigan Rogel Cancer Center, Ann Arbor

48202

Henry Ford Hospital, Detroit

63110

Washington University School of Medicine-Center for Clinical Imaging Research, St Louis

70131

Ochsner Clinic Foundation, New Orleans

77030

The University of Texas MD Anderson Cancer Center, Houston

84112

Center for Quantitative Cancer Imaging at Huntsman Cancer Institute, Salt Lake City

85013

St. Joseph's Hospital and Medical Center, Phoenix

90404

John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica

94118

University of California, San Francisco, San Francisco

06519

Yale School of Medicine, New Haven

Sponsors
All Listed Sponsors
collaborator

Precision For Medicine

INDUSTRY

lead

Blue Earth Diagnostics

INDUSTRY